16 stories found
Several companies, including Recruit Holdings, Daimler Truck, Arteris, and ICU Medical, have updated or raised their financial outlooks for fiscal year 2026. These revisions reflect various factors such as strong performance, strategic initiatives, and market conditions.
GoodRx Holdings, Inc. is reported to be strengthening its recurring revenue base through its new 'Companion' offering, enhancing its market position.
Russian President Vladimir Putin visited Beijing to meet with Chinese President Xi Jinping, following a recent meeting between Xi and former US President Donald Trump. This series of high-level diplomatic engagements is being closely watched for its implications on global power dynamics and international relations.
Several companies, including CleanSpark, 3D Systems, and Constellation Energy, have released or previewed their Q1 or Q2 2026 earnings. These reports provide financial updates and outlooks for the respective quarters.
A summary of GoodRx Holdings, Inc.'s Q4 2025 earnings call has been released, outlining the company's financial performance.
60 Degrees Pharmaceuticals has announced a partnership with GoodRx to enhance patient access to its malaria prevention drug, ARAKODA.
GoodRx CEO Wendy Barnes stated that strategic partnerships are significantly contributing to strong earnings, even as the company's traditional prescription business experiences a decline.
GoodRx has introduced a new subscription service designed to provide access to cheap or free generic prescription drugs.
Financial commentator Jim Cramer has provided a range of stock recommendations, advising on whether to buy, hold, or avoid various companies including TJX, Caterpillar, Eli Lilly, and Cloudflare. He also expressed regret over selling Cisco and cautioned against buying certain stocks at their current highs.
Several companies across various sectors have released their financial forecasts and guidance for 2026. These projections detail expected revenues, adjusted EBITDA, and other key performance metrics for the upcoming fiscal year.
GoodRx (GDRX) has released the transcript of its fourth-quarter 2025 earnings call, providing detailed insights into the company's financial performance and outlook.
GoodRx, a leader in prescription savings, is now venturing into the broader American healthcare journey, driven by rising consumer costs and a demand for predictable pricing and simpler navigation.
Seeking Alpha analysts have issued upgrades and downgrades for several prominent stocks, including Nvidia (NVDA), Meta (META), GoodRx (GDRX), and JPMorgan (JPM).
An analysis compares the revenue performance of GoodRx and Hims & Hers Health, highlighting stagnation in one company versus growth in the other.
GoodRx has published highlights from its first-quarter earnings call, providing insights into the company's recent financial performance.
GoodRx anticipates at least 30% revenue growth in its Pharma Direct segment by 2026, driven by a strategic shift towards pharmaceutical manufacturer solutions.